- Antibiotic Resistance in Bacteria
- Antibiotics Pharmacokinetics and Efficacy
- Childhood Cancer Survivors' Quality of Life
- Pneumocystis jirovecii pneumonia detection and treatment
- Paraoxonase enzyme and polymorphisms
- Dietary Effects on Health
- Gut microbiota and health
- Health Systems, Economic Evaluations, Quality of Life
- Antibiotic Use and Resistance
- Diet and metabolism studies
- Pharmaceutical and Antibiotic Environmental Impacts
Capital Medical University
2024
Beijing Chao-Yang Hospital
2024
Shanghai Sixth People's Hospital
2014
Dysbiosis of the gut microbiota has been implicated in hypertension, and drug-host-microbiome interactions have drawn considerable attention. However, influence angiotensin receptor blocker (ARB)-shaped on host is not fully understood. In this work, we assessed alterations blood pressure (BP), vasculatures, intestines following ARB-modified microbiome treatment evaluated changes intestinal transcriptome serum metabolome hypertensive rats. Hypertensive patients with well-controlled BP under...
A clinical strain of extended-spectrum β-lactamase-producing Escherichia coli E265, with a fosfomycin MIC 512 μg ml(-1), was isolated from an inpatient hospital-acquired pneumonia. This negative for known fos genes, had no mutation in the target enzyme by polymerase chain reaction amplification and functional transport systems uptake. Fosfomycin resistance could be transferred E265 to E. J53 azide(R) conjugation. The DNA fragment containing determinants cloned into TOP10. minimal inhibitory...
Abstract Mutations in the Paraoxonase 1 ( Pon1 ) gene underlie aging, cardiovascular disease, and impairments of nervous gastrointestinal systems are linked to intestinal microbiome. The potential role modulating microbiota serum metabolites is poorly understood. present study demonstrated that mice with genomic excision by a multiplexed guide RNA CRISPR/Cas9 approach exhibited disrupted gut microbiota, such as significantly depressed alpha‐diversity distinctly separated beta diversity,...